Literature DB >> 33256496

Use of Medical Cannabis to Treat Traumatic Brain Injury.

Danielle C Hergert1, Cidney Robertson-Benta1, Veronik Sicard1, Daniela Schwotzer2, Kent Hutchison3, Dan P Covey2, Davin K Quinn4, Joseph R Sadek4,5,6, Jacob McDonald2, Andrew R Mayer1,4,5,7.   

Abstract

There is not a single pharmacological agent with demonstrated therapeutic efficacy for traumatic brain injury (TBI). With recent legalization efforts and the growing popularity of medical cannabis, patients with TBI will inevitably consider medical cannabis as a treatment option. Pre-clinical TBI research suggests that cannabinoids have neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis use has consistently shown to have detrimental effects. Our review identified a paucity of high-quality studies examining the beneficial and adverse effects of medical cannabis on TBI, with only a single phase III randomized control trial. However, observational studies demonstrate that TBI patients are using medical and recreational cannabis to treat their symptoms, highlighting inconsistencies between public policy, perception of potential efficacy, and the dearth of empirical evidence. We conclude that randomized controlled trials and prospective studies with appropriate control groups are necessary to fully understand the efficacy and potential adverse effects of medical cannabis for TBI.

Entities:  

Keywords:  THC; cannabidiol; cannabinoids; medical cannabis; medical marijuana; traumatic brain injury

Mesh:

Substances:

Year:  2021        PMID: 33256496      PMCID: PMC8260892          DOI: 10.1089/neu.2020.7148

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   4.869


  162 in total

Review 1.  Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.

Authors:  A Batalla; J A Crippa; G F Busatto; F S Guimaraes; A W Zuardi; O Valverde; Z Atakan; P K McGuire; S Bhattacharyya; R Martín-Santos
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Rates of major depressive disorder and clinical outcomes following traumatic brain injury.

Authors:  Charles H Bombardier; Jesse R Fann; Nancy R Temkin; Peter C Esselman; Jason Barber; Sureyya S Dikmen
Journal:  JAMA       Date:  2010-05-19       Impact factor: 56.272

Review 3.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

4.  Mental Health and Medical Cannabis Use among Youth and Young Adults in Canada.

Authors:  Elle Wadsworth; Cesar Leos-Toro; David Hammond
Journal:  Subst Use Misuse       Date:  2019-11-20       Impact factor: 2.164

Review 5.  Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.

Authors:  Jesse D Kosiba; Stephen A Maisto; Joseph W Ditre
Journal:  Soc Sci Med       Date:  2019-06-08       Impact factor: 4.634

Review 6.  Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors:  Kevin P Hill
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

7.  Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep.

Authors:  Brian J Piper; Rebecca M DeKeuster; Monica L Beals; Catherine M Cobb; Corey A Burchman; Leah Perkinson; Shayne T Lynn; Stephanie D Nichols; Alexander T Abess
Journal:  J Psychopharmacol       Date:  2017-04-04       Impact factor: 4.153

8.  Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample.

Authors:  Lewei A Lin; Mark A Ilgen; Mary Jannausch; Kipling M Bohnert
Journal:  Addict Behav       Date:  2016-05-17       Impact factor: 3.913

9.  Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients.

Authors:  Philippe Lucas; Eric P Baron; Nick Jikomes
Journal:  Harm Reduct J       Date:  2019-01-28

10.  Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial.

Authors:  Rachel L Tomko; Nathaniel L Baker; Erin A McClure; Susan C Sonne; Aimee L McRae-Clark; Brian J Sherman; Kevin M Gray
Journal:  Drug Alcohol Depend       Date:  2017-11-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.